Abstract:Although initial experiences with FK 506 rescue therapy for acute hepatic allograft rejection have provided promising results, analysis of available data indicates that inferior results are obtained when FK 506 rescue therapy is initiated in the latter stages of rejection. Since its initial availability, we have applied an aggressive approach towards FK 506 rescue therapy based on early conversion and assiduous dosing. We have reviewed our experience with this approach in patients with refractory hepatic allograft rejection to provide an assessment of this approach. Sixteen patients were treated for corticosteroid and OKT3‐resistant acute hepatic allograft rejection. Fourteen patients were treated for cellular rejection and 2 for humorally‐mediated rejection. Median followup was 7.3 months posttransplant and 6.0 months post‐initiation of FK 506 therapy. Median time to first rejection was 8 days and median time to FK 506 therapy was 29 days. Laboratory values at the time of initiation of FK 506 therapy included: mean serum bilirubin, 4.0±3.1 mg/dl and SGPT 136±105 Ul. Prior to FK 506 therapy, patients received an average. of 35.5±19.1 mg/kg of bolus/taper corticosteroids (prednisone equivalent) and 11.25±4.8 days of OKT3 therapy. FK 506 therapy was succesful in reversing all episodes of rejection. Median time to rejection reversal with FK 506 rescue therapy was 23 days (mean±SD, 27.6±16.7 days) in patients with cellular rejection. Time to rejection reversal was 26 and 28 days in the 2 patients with humoral rejection. Patient and graft survival at 6 months were 100%/100%, and 94%94% at 12 months. Graft loss to rejection was not observed. Significant CMV infections occurred in 44% of patients: CMV hepatitis in 5 (31%), CMV pneumonitis in 1 patient (6%), and CMV viremia alone in 1 (6%). The mean time to CMV disease occurred on posttransplant day 29, which corresponded to a median of 5 days of FK 506 therapy, suggesting that CMV disease was more probably the result of intense immunosuppression which was administered prior to FK 506 therapy. These results indicate that an aggressive approach to FK 506 rescue therapy in patients with refractory hepatic allograft rejection: 1) provides high rates of reversal, 2) provides excellent patient and graft‐survival rates in a subset of patients at high risk for allograft loss, 3) appears to provide similar results for cellular and humorally‐mediated hepatic allograft rejection, and 4) allows for effective, simultaneous treatment of CMV disease and rejection. Continued attempts. to reverse OKT3‐resistant hepatic allograft rejection with conventional approaches (corticosteroids, repeat OKT3 therapy, polyclonal antilymphocyte preparations) may no longer be warranted.

The use of OKT3 in recipients of pancreatic, pulmonary, and bone marrow allografts

OKT3 for induction of immunosuppression and treatment of rejection in cardiac allograft recipients

OKT3 for induction of immunosuppression in renal transplantation

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

OKT3 for treatment of rejection in renal transplantation

OKT 3 for rejection reversal in pediatric renal transplantation

Clinical experience with OKT3 monoclonal antibody for treatment of acute renal allograft rejection based on sequential histological evaluation

Clinical Study of Single-Dose of Recombinant Humanized Anti-Cd3 Monoclonal Antibody Injection in Kidney Transplant Recipients

OKT3 and viral disease in pediatric liver transplant recipients

Standard versus low‐dose OKT3 induction therapy of cadaveric renal transplants: Comparison of outcome data versus OKT3 dose and serum levels

Increased risk of lymphoproliferative disorders following the use of OKT3 in cardiac transplantation

Treatment of severe rejection of kidney transplants with Orthoclone OKT3

Murine monoclonal CD‐3 antibody in cardiac transplantation: Antirejection treatment and preliminary results in a prospectively randomized trial for prophylaxis

The effect of rabbit antithymocyte serum (RATS) and OKT3 on peripheral blood mononuclear cell subsets following renal transplantation

Immunologic monitoring during OKT3 therapy

FK 506 rescue therapy for hepatic allograft rejection: Experience with an aggressive approach

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Human in vivo antigenic modulation of T lymphocytes induced by OKT3 for preventi on of transplant rejection

Effect of Different Induction Therapies on the Clinical Outcomes of ABO-incompatible Living Donor Kidney Transplantation Recipients

Abo-Incompatible Living Kidney Transplantation

ABO‐incompatible Living Kidney Transplantation